Similarly, another Kat5/TIP60 inhibitor, NU9056, has recently been shown to reduce fibrotic gene expression, α-SMA levels, and collagen deposition in both murine and human CFs, further supporting the therapeutic relevance of targeting Kat5 in cardiac fibrosis [36]. Here, KAT5 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.